A deterministic snapshot of the global clinical-trial landscape — every figure reproducible from the ClinicaLister knowledge graph.
Registered in the past 7 days.
Trials that moved to a new overall status.
Terminations, withdrawals and suspensions — with the sponsor's stated reason.
Other - Assessing accrual feasibility
Study closed to accrual given widespread availability of the similar marketed product, Lutathera(R), and the corresponding lack of accrual to the study.
target number of inclusion not reached
initially stopped recruitment in COVID pandemic, now different prosthesis being use in the Sponsor NHS Trust, unlikely study will restart.
target number of inclusion not reached (65/256)
target number of inclusion not reached
The study strategy was adjusted, and the company decided to terminate the study early
\<75% participation
Due to loss of funding
CKD participants we recruited do not have elevated ADMA, which is the main premise for this intervention. We noticed this with first cohort studied and collected blood from our other ongoing CKD studies, which further solidified and why terminated.
Study is withdrawing to the retirement of the PI.
0 approvals month-to-date.
| Sponsor | Drug | Approved |
|---|---|---|
| CMP DEV LLC | CLONIDINE HYDROCHLORIDE | 2026-07-29 |
| FRESENIUS KABI USA LLC | Unknown | 2026-07-29 |
| APOTEX | Ruxolitinib | 2026-07-29 |
| LNK INTL INC | POLYETHYLENE GLYCOL 3350 | 2026-07-29 |
| MYLAN | SUGAMMADEX SODIUM | 2026-07-28 |
| QILU PHARM HAINAN | SUGAMMADEX SODIUM | 2026-07-28 |
| ZENARA | SUGAMMADEX SODIUM | 2026-07-28 |
| MSN | SUGAMMADEX SODIUM | 2026-07-28 |
| HIKMA | SUGAMMADEX SODIUM | 2026-07-28 |
| STERISCIENCE | SUGAMMADEX SODIUM | 2026-07-28 |
| ESJAY PHARMA | GLYCEROL PHENYLBUTYRATE | 2026-07-28 |
| VIATRIS SPECIALTY | Unknown | 2026-07-28 |
| BAXTER HLTHCARE CORP | DIAZEPAM | 2026-07-28 |
| LUPIN | SUGAMMADEX SODIUM | 2026-07-28 |
| FRESENIUS KABI USA | SUGAMMADEX SODIUM | 2026-07-28 |
7.7% of the last year's EMA authorisations were conditional.
None authorised this period.
3 new · 0 resolved · 105 currently active.
| Newly reported shortage | Posted |
|---|---|
| Doxycycline Hyclate Tablet, Delayed Release | 2026-07-30 |
| Glycopyrrolate Injection | 2026-07-30 |
| Fluticasone Propionate and Salmeterol Xinafoate Aerosol, Metered | 2026-07-27 |
Most new trials this week.
Industry sponsors, new trials · trailing 28 days.
New links where the molecule is the studied intervention.
FDA device clearance data is current; MAUDE adverse-event and recall feeds lag ~1-2 months.
Whole-corpus totals and rankings, recomputed every week.
Monthly new registrations across ClinicalTrials.gov. Puts the weekly count in context.
By linked trials (MONDO rollup).
Among the 70,435 trials with a mapped site location — not the whole corpus.
| Sponsor | Trials |
|---|---|
| Cairo University | 4,777 |
| Assiut University | 4,728 |
| GlaxoSmithKline | 3,620 |
| National Cancer Institute (NCI) | 3,551 |
| Assistance Publique - Hôpitaux de Paris | 3,531 |
| AstraZeneca | 3,465 |
| Pfizer | 3,291 |
| Mayo Clinic | 3,224 |
| M.D. Anderson Cancer Center | 3,014 |
| Novartis Pharmaceuticals | 2,680 |
| National Taiwan University Hospital | 2,584 |
| Massachusetts General Hospital | 2,555 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 2,436 |
| Boehringer Ingelheim | 2,283 |
| University of California, San Francisco | 2,147 |
| Stanford University | 2,140 |
| Merck Sharp & Dohme LLC | 2,136 |
| Riphah International University | 2,124 |
| Hoffmann-La Roche | 2,079 |
| Eli Lilly and Company | 2,071 |
| Duke University | 2,046 |
| Memorial Sloan Kettering Cancer Center | 1,941 |
| Seoul National University Hospital | 1,884 |
| Ain Shams University | 1,862 |
| Hospices Civils de Lyon | 1,833 |
| Condition | Trials |
|---|---|
| breast cancer | 11,784 |
| obesity disorder | 9,554 |
| type 2 diabetes mellitus | 9,131 |
| chronic pain syndrome | 8,799 |
| cancer | 8,223 |
| HIV infectious disease | 8,205 |
| COVID-19 | 7,641 |
| non-small cell lung carcinoma | 6,367 |
| hypertensive disorder | 6,123 |
| diabetes mellitus | 6,121 |
| cerebrovascular disorder | 6,005 |
| colorectal cancer | 6,005 |
| coronary artery disorder | 5,935 |
| prostate cancer | 5,843 |
| depressive disorder | 5,830 |
| cardiovascular disorder | 5,601 |
| heart failure | 4,894 |
| anxiety disorder | 4,890 |
| injury | 4,480 |
| Parkinson disease | 4,431 |
| asthma | 4,416 |
| cognitive disorder | 4,171 |
| lung cancer | 4,058 |
| benign essential hypertension | 3,875 |
| neuralgia | 3,825 |
| Molecule | Trials |
|---|---|
| carboplatin | 7,157 |
| paclitaxel | 5,543 |
| isoniazid | 5,321 |
| prednisolone | 5,249 |
| cyclophosphamide | 5,113 |
| ropivacaine | 4,842 |
| dexamethasone | 4,786 |
| bevacizumab | 4,589 |
| cisplatin | 4,461 |
| lidocaine | 3,602 |
| aspirin | 3,361 |
| gemcitabine | 3,172 |
| bupivacaine | 3,112 |
| desoxycorticosterone acetate | 2,982 |
| pembrolizumab | 2,978 |
| metformin | 2,960 |
| sitagliptin and metformin hydrochloride | 2,956 |
| rituximab | 2,928 |
| meprednisone | 2,850 |
| dapagliflozin metformin hydrochloride | 2,788 |
| sitagliptin metformin hydrochloride | 2,766 |
| docetaxel | 2,758 |
| linagliptin and metformin hydrochloride | 2,753 |
| fluorouracil | 2,706 |
| alogliptin and metformin hydrochloride | 2,695 |
Standing competitive & regulatory landscape — who is developing what, at which stage, and which drugs are about to lose exclusivity.
Active trials by the most prolific industry sponsors, split by phase.
| Phase 1 | Phase 2 | Phase 3 | |
|---|---|---|---|
| GlaxoSmithKline | 1,091 | 861 | 890 |
| AstraZeneca | 1,018 | 551 | 802 |
| Pfizer | 1,175 | 709 | 654 |
| Novartis Pharmaceuticals | 508 | 835 | 735 |
| Boehringer Ingelheim | 1,066 | 322 | 399 |
| Merck Sharp & Dohme LLC | 698 | 550 | 738 |
| Hoffmann-La Roche | 491 | 480 | 568 |
| Eli Lilly and Company | 826 | 535 | 548 |
FDA drugs whose exclusivity expires soon (distinct substances).
| Drug (losing exclusivity < 6mo) | Expires |
|---|---|
| Fedratinib Hydrochloride | 2026-08-16 |
| Valbenazine Tosylate | 2026-08-18 |
| Gallium Ga-68 Edotreotide | 2026-08-21 |
| Cobicistat | 2026-08-22 |
| Difelikefalin Acetate | 2026-08-23 |
| Sofosbuvir | 2026-08-28 |
| Ledipasvir; Sofosbuvir | 2026-08-28 |
| Citalopram Hydrobromide | 2026-09-16 |
| Phentolamine Mesylate | 2026-09-25 |
| Atogepant | 2026-09-28 |
| Miglustat | 2026-09-28 |
| Technetium Tc-99m Labeled Carbon | 2026-09-29 |
| Patiromer Sorbitex Calcium | 2026-10-02 |
| Risdiplam | 2026-10-03 |
| Dexamethasone | 2026-10-03 |
FDA drugs carrying each designation.
Molecules most often used as the comparator arm (the standard to beat).
Every figure is a deterministic SQL aggregate over the ClinicaLister knowledge graph as of the report date. No figure is AI-generated or estimated; each is reproducible and traceable to its public source.
Sources: ClinicalTrials.gov · EU CTIS · openFDA (drugs, devices, shortages) · EMA · MONDO disease ontology · GSRS · GUDID · Europe PMC / PubMed
Every figure above is a deterministic aggregate over the ClinicaLister knowledge graph — and one click deep in the product, with a source behind each claim.
Machine-readable: download this edition as JSON above, or query the full archive programmatically via the public get_public_report_snapshots endpoint.